The field of erectile dysfunction (ED) management over time has witnessed assorted interventions to enable the male to perform sexual intercourse. In recent times, major progress in ED research has led to increasingly effective treatments based on a refined knowledge of the scientific basis for penile erection. Current concepts suggest that therapeutic prospects on the horizon include novel pharmacotherapies, growth factor therapy, gene therapy and regenerative medicine. The purpose of this review is to present the foundations for future therapies in ED management.
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Erectile dysfunction (ED) management has moved forward substantially in the past 25 years with the introduction of a host of remarkable therapeutic options. Not too long ago, management for ED was directed largely towards psychosocial or hormonal factors, in accordance with the presumption that these were causative conditions for the disorder. Hence, therapy was generally administered in the forms of psychoanalysis, sex therapy, and hormonal interventions. If such management did not work, alternative strategies were used ranging from herbal supplements presumed to enhance sexual performance to mechanical devices. For the latter, early penile implants of the 1950's and vacuum-pump technology of the late 1960's were affirmed to create penile rigidity, obviating the necessity for complete knowledge or application of the physiology or biochemical properties of the erectile response.
In recent times, scientific advances in the physiology and molecular mechanisms of penile erection have spawned innovative treatments for ED. In the early 1970's, a rather ingenious approach was the description of penile revascularization, designed to restore penile blood flow function and the basis for blood engorgement of the penis. It so turned out that these surgeries would represent only a limited role in the armamentarium of treatments for ED, serving the narrow group of men with ED associated with traumatic rupture of major pudendal arteries supplying blood to the penis. Subsequently, major progress was gained within the realm of pharmacologic therapies---treatments which were based on an evolving understanding of the chemistry associated with corporal tissue and vascular reactivity within the penis. In series, these were intracavernosal pharmacotherapy introduced in the early 1980's, intraurethral pharmacotherapy introduced in the mid-1990's, and oral pharmacotherapy introduced in the late 1990's---all demonstrated through rigorous basic scientific and clinical investigation to represent valid, effective options for managing ED. 4 Along with this revolution in ED therapies, there came new ways of thinking about evaluating and assigning therapy to patients. First to come was the definition of the problem more accurately and euphemistically as that of "the inability to attain and maintain erections of sufficient quality to permit satisfactory sexual intercourse" (NIH Consensus Statement, 1992 ).
In addition, it was accepted that ED carried a subjective attribution and correctly involved patient and partner in the identification, evaluation, and initiation of appropriate therapy. In step with this new clinical practice approach, lesser invasive and otherwise reversible therapies were promoted. This movement further suggested the increasing opportunity for patients to be decision-makers with regard to their ED management. Oral medication such as oral phosphodiesterase type 5 (PDE5) inhibitors is recognized to serve as first-line therapy; vacuum devices, and penile injections represents second-line therapies; and penile prosthesis surgeries is designated as third-line therapy.
Current interventions for ED are consequences of significant advances in the field of sexual medicine. New therapies particularly indicate an evolution in the cellular and molecular science of erection physiology. Epidemiologic associations of disease states with impaired vascular biology, neurophysiology, and endocrinology have also helped to revise thinking about the pathophysiologic mechanisms responsible for ED. It is now recognized that risk factors for ED include increasing age, cardiovascular diseases, diabetes mellitus, environmental risk factors such as cigarette smoking, and lifestyle factors such as lack of physical activity. Undoubtedly, collaborative scientific activity involving specialists from diverse biomedical disciplines has fostered new scientific understanding and engendered strategies that have led to the effective management of many men with ED worldwide. At this critical juncture in the field, particularly 5 with the availability of effective oral therapy for ED, the question arises as to whether we have truly achieved "ideal therapy"? In fact, although current offerings are more easily administered, scientifically based, and clinically proven to be effective than those in the past, they still have their shortcomings. These include the observations that they are not always effective or convenient to use while also having limited spontaneity. Furthermore, they do not truly correct, cure, or prevent ED. These shortcomings are well recognized in the field, and many investigators continue to explore improved treatments for ED which would meet heightened objectives for ideal therapy.
From this perspective, this essay is intended to present several major biomedical research directions which may foster applicable clinical therapeutics for ED in the future. Broadly speaking, such directions include pharmacotherapy, growth factor therapy, gene therapy, and regenerative medicine, all consistent with advancing knowledge of key molecular targets as well as prime biological constituents underlying erection physiology. In reviewing these, it is my hope to provide a glimpse of what may be promising, up-and-coming ways that will enable clinicians to even better manage ED beyond current options in the field.
Pharmacotherapy
Among therapeutic prospects for ED, the pharmacotherapeutic approach to managing has gained prominence over recent years. This observation is hardly a surprise, with recognition of the fact that pharmacologic agents serve to replicate effector molecules and otherwise activate signaling mechanisms involved in the production of the erectile response. In this regard, therapeutic strategies are commonly categorized according to peripheral and central levels of 6 effects, in reference to the neurologic system. This reference also acknowledges that regulation principally involves the neuroaxis, with contributions from endocrine and paracrine regulators.
Both peripherally and centrally, pharmacologic management commonly adheres to the dichotomous strategic schemes of suppressing antierectile mechanisms or promoting proerectile mechanisms, or some combination of both.
In the periphery with reference to the pelvis and penis, current concepts of approaches to Recent science of the molecular basis of penile erection has confirmed the major role of the RhoA/Rho-kinase signaling pathway as a dominant regulator of vascular smooth muscle contraction throughout the body as well as in the penis (Mills et al, 2001 ). The pathway actually represents a molecular site of convergence for contractile mediators (e.g., norepinephrine, endothelin, and angiotensin II), such that the pathway serves as the effector basis for the molecular actions of these mediators in vascular tissue. Based on this relatively new knowledge, it is highly anticipated that pharmacotherapeutic strategies will be developed targeting the RhoA/Rho-kinase signaling pathway in the penis. A particular focus of attention for pharmacotherapeutic development is whether the actions of conceivably selective stimulatory or 7 inhibitory binding proteins for this pathway operate in the penis and may be exploited to drive erectile responses specifically and without adverse consequences elsewhere in the body .
Peripheral strategies which center on promoting proerectile mechanisms are quite diverse and include nitric oxide (NO) signaling pathway effectors, phosphodiesterase (PDE) inhibitors, prostanoids, cholinergic receptor agonists, vasoactive peptides, and potassium channel openers (Andersson, 2001 ). All of these strategies are based on scientific principles of neurophysiology and vascular smooth muscle biology having relevance for the penis. At this time, the NO/cyclic guanosine monophosphate (cGMP)/cGMP-dependent protein kinase I pathway serves as the principal regulatory basis for penile erection . This pathway offers multiple molecular sites for pharmacologic targeting, including catalytic enzymes, biochemical cofactors and products, and degradative enzymes. This pathway has already been exploited for clinical practice. Most well known are the commercially available, orally effective PDE5 inhibitors such as sildenafil, vardenafil, and tadalafil (Corbin, 2004) . These medications pharmacologically act by blocking the actions of the degradative enzyme PDE5 in the penis (which degrades the second messenger molecule of NO signaling, cGMP). In this manner, PDE5 inhibitors potentiate the corporal smooth muscle relaxation effects of this signaling pathway. The non-specific PDE inhibitor papaverine used familiarly in intracavernosal pharmacotherapeutic regimens is another example of this therapeutic strategy. The predominance of the NO signaling pathway in erection physiology indicates that it will continue to draw interest as an avenue to modulate the erectile response for clinical purposes. For the future, investigators may advance specific therapies based on targeted molecular mechanisms beyond PDE5 inhibition. Of particular interest, the development of guanylate cyclase activators which serve to drive the signaling pathway 8 independent of NO stimulation has been studied at the preclinical level with hopeful potential clinically (Brioni et al, 2002) .
Prostanoids have been shown to control smooth muscle physiology in the penis and its representative chemical prostaglandin E 1 (also known as alprostadil) has been used primarily for the intracavernosal pharmacotherapy of ED (Cawello et al, 1997) . Ongoing studies to characterize prostanoid metabolites, receptors, and mechanisms of action in the penis may lead to meaningful pharmacotherapeutic strategies in the future. Cholinergic actions in the penis are understood to contribute to penile erection as a neuronal mechanism stimulating the endothelial release of vasoactive substances including endothelial NO (Andersson, 2001 ). This knowledge suggests that therapies driving cholinergic stimulation in the penis could be attractive as a therapeutic strategy for ED. The possibility of developing pharmacotherapy based on neuropeptide and vasoactive peptide actions in the penis remains of interest and generates from strong basic scientific work showing that these chemicals do indeed contribute to the regulatory biology of erectile tissue (Becker et al, 2001; Guidone et al, 2002) . Additional pharmacotherapy is likely to generate from improved knowledge regarding electrophysiologic properties of smooth muscle including ion channel functions involved in corporal smooth muscle biology.
Therapies based on ion homeostasis mechanisms within corporal smooth muscle tissue seem attractive because of the fundamental regulatory basis associated with ionic movements that determine tissue contractility (Christ et al, 1993) . Early studies have been conducted showing that potassium channel opener mechanisms can be applied for pharmacotherapeutic purposes for ED (Holmquist et al, 1990; Venkateswarlu et al, 2002) .
Pharmacotherapy at central levels of erection control offers an entirely different approach in the management of ED. The concept that central pharmacotherapeutics could be exploited for 9 ED management seems intuitive with the understanding that a whole host of erectogenic stimuli processed at brain and spinal cord levels elicit penile erection (Giuliano et al, 1995) . However, Another mechanism that may converge on oxytocinergic neurons within hypothalamic nuclei is represented by the melanocortinergic regulatory pathway (Wessells et al, 2005) . In fact, although results have only confirmed safety and not proven therapeutic efficacy yet (Burnett and Lue, 2006) . Ongoing fervent investigations may delineate the next level of compounds or strategic formulation of drugs having beneficial effects for human conditions. It is noteworthy that this therapeutic direction offers a corrective approach to the problem of neurogenic ED, with the potential to restore normal erectile function. Key issues are whether therapies related to this field can be administered without causing adverse proliferative effects on structures elsewhere in the body. This matter is of particular concern for nerve growth factor therapy that may be suited for the setting of radical prostatectomy in which there may be concerns of growth proliferative effects on possibly remnant prostate cancer cells after surgery. It will also be essential to develop ways to control the manner of this therapeutic effect on nerve growth.
Growth factor therapy is certainly relevant because of the predominance of vascular disease states impacting negatively on erectile function. In fact, emphasis has been given to the role of endothelial dysfunction as a key pathogenic factor underlying a whole host of cardiovascular clinical states. It is understood that the vascular endothelium within the penile vasculature is vital for biological processes ranging from hemodynamic regulation to vascular homeostasis.
Significant experimental work in this area also using rodent animal models primarily have clarified the role for angiogenic factors and their likely trophic effects on vascular smooth muscle cell function in the penis (Burchardt et al, 2005; Xie et al, 2008) . A host of molecular factors have been studied such as vascular endothelial growth factor and basic fibroblast growth factor. The translation of these studies for the clinical treatment of vasculogenic ED has gained traction in recent years, and future clinical trials hold promise that this form of growth factor therapy will be useful. The idea to restore or promote vascular/endothelial mechanisms within the penis is attractive. Similar to the premise of nerve growth factor therapy, therapeutic strategies for the growth and function of the penile vasculature offer the potential to restore normal erectile function.
Gene Therapy
Gene therapy suggests the idea of a science fiction approach to managing ED. However, this approach may indeed represent a new frontier for the management of this problem, with possible advantages for prevention of ED or even recovery of erectile function in the face of disease states injurious to penile health (Strong et al, 2008) . The concept refers to the introduction of foreign genetic material into human cells which either restore or supplement normal cellular function that is defective or otherwise antagonize the functional effects of expression of the mutant genetic phenotype. The penis does represent an ideal location for gene therapy, given its external location and accessibility for efficient genetic manipulation. In addition, the rather homogenous content of parenchyma within the penis suggests that the delivery can be delivered and dispersed consistently. The way gene therapy works requires that only a proportion of cells becomes transfected, and given the properties of the erectile tissue response by which the effect of delivery can be transferred intercellularly by gap junctions of corporal smooth muscle cells the penis is an attractive organ to pursue gene therapy.
Gene therapeutic approaches have been categorized according to their delivery designs, through viral (e.g., adenoviruses, adeno-associated viruses, retroviruses) or non-viral (e.g., naked
DNA, plasmid DNA, liposomes) vectors or other cell-based (e.g., myoblasts, endothelial cells) 13 delivery systems (Christ and Melman, 1998) has shown safety effects and possibly efficacy benefits (Melman et al, 2006) . This trial consisted of only a small number of patients and did not include a control arm. Thus, definitive judgments 14 about the success of gene therapy in humans to treat erectile dysfunction remain limited.
However, this study has provided enough interest to stimulate further investigation in this area.
The future management of ED based on gene therapeutic prospects is highly considered.
It is attractive to propose a therapeutic approach that may have long-term effects in managing or even preventing ED. This option may well be considered in combination with other therapies thereby reducing dose requirements and lessening adverse effects associated with other therapies.
With this promise ahead, it is important to acknowledge challenges that persist and will need to be overcome to bring this therapy to fruition. Attention will need to be given to the selection of preferred gene products or combinations thereof that will be broadly useful or otherwise specifically advantageous for select presentations of ED. In addition, it will be necessary to overcome safety hurdles, which have been associated with gene therapeutic management in general at the clinical level.
Regenerative Medicine
Concepts of tissue reconstruction have been applied to biological constituents structurally responsible for penile erection. Accordingly, regenerative medicine for the penis implies techniques ranging from tissue engineering to stem cell therapy, which are designed to reconstitute tissues relevant for the erectile response from penile nerves to the corpus cavernosum itself.
Scientific work in the area of structural repair or reconnection of penile nerves has been done preclinically and clinically with primary interest for the application of post-radical prostatectomy ED (Burnett and Lue, 2006) . The rationale is to provide a substitute for injured 15 or excised cavernous nerves that may occur during radical prostatectomy. Nerve grafting conduits have been described ranging from autotransplanted nerve structures to synthetic nerve guides, which can be interposed in the course of the autonomic penile innervation. On a grander scale, progress has been made to recompose corporal tissue, which would have applications in clinical conditions of significant penile tissue loss (Falke et al, 2003) . This therapeutic discipline combines engineering of corporal tissue components and advanced delivery methods for genes and growth factors that promote organogenesis. Despite the impressive body of preclinical work that has been done, significantly more progress is needed to bring concepts of regenerative medicine to the clinical arena for the management of ED. The feasibility of grafting procedures for penile nerve restoration is certainly understood, although convincing support for the success of this therapeutic endeavor remains unclear. For corporal tissue reconstruction, a greater objective will be needed to fulfill architectural, biomechanical, and functional requirements of native corpora cavernosa. The development of cell delivery vehicles and vectors for genes and growth factors required for functional penile tissue will be paramount for advancing this therapeutic approach.
Summary
From antiquity to the present, the management of erectile dysfunction (ED) has progressed substantially. Historical therapies derived largely from rudimentary if not theoretical beliefs regarding the psychological, hormonal, or chemical factors impacting penile erection.
Alternatively, mechanical devices were developed obviating scientific understanding of erection mechanisms, although they produce an effective means for rigidity of the penis when needed for 16 sexual intercourse. More recently, biological research surrounding this topic has yielded an increasingly advanced understanding of the science of the erectile response. This research has contributed to scientifically purposeful treatments for ED, and as such work has rapidly continued a new stage has been set for developing therapeutic options that may correct or even prevent this sexual dysfunction. Several categories of therapeutic advances are apparent, including novel pharmacotherapies, growth factor therapy, gene therapy and regenerative medicine. Amid these exciting scientific developments, the future of ED management is full of promise.
